PharmiWeb.com - Global Pharma News & Resources
14-Jan-2019

LEXAPRO Drug Profile, 2019 - Patents, Clinical Trials, Drug Prices, Annual Sales Revenues and Raw API Sources - ResearchAndMarkets.com

The "LEXAPRO Drug Profile, 2019" report has been added to ResearchAndMarkets.com's offering.

LEXAPRO Drug Profile, 2019 is part of a deep library of business intelligence on biopharmaceutical drugs. The report focuses on LEXAPRO and covers the following critical aspects of this drug:

  • United States patents
  • Expired United States patents
  • FDA Paragraph IV patent challenges
  • District Court patent litigation
  • European supplementary protection certificates (SPCs)
  • Clinical trials
  • Drug prices
  • Annual sales revenues
  • Finished product suppliers
  • Raw active pharmaceutical ingredient (API) sources

Topics Covered

  • Profile for LEXAPRO
  • US Patents
  • Expired US Patents
  • Paragraph IV Patent Challenges
  • US District Court Litigation
  • International (ex US) Patents
  • Supplementary Protection Certificates
  • Clinical Trials
  • Drug Prices - Average Pharmacy Cost
  • Drug Prices - Best Wholesale Price
  • Annual Sales Revenues
  • Finished Product Suppliers
  • Bulk API Sources

Companies Featured

  • Allergan Inc.
  • Mylan Institutional Inc.
  • Blenheim Pharmacal Inc.
  • Bryant Ranch Prepack
  • Novoseek
  • Molport
  • Abi Chem
  • Chemmol
  • Chembase.Cn
  • Acesobio
  • Ak Scientific Inc. (Aksci)
  • Tractus
  • Abachemscene
  • Medchemexpress Mce
  • Wolves R&D Chemical
  • A&J Pharmtech Co. Ltd.
  • An Pharmatech
  • Syntree
  • Tocris Bioscience
  • Oxchem Corporation
  • Targetmol
  • Boc Sciences
  • Phion Ltd
  • Apexbio Technology
  • Labseeker
  • Yuhao Chemical
  • LGC Standards
  • Dc Chemicals
  • Ochem
  • Labnetwork
  • Ambinter
  • Bld Pharm
  • Biochempartner
  • Hairui Chemical
  • and many more...

For more information about this report visit https://www.researchandmarkets.com/research/h3vfcv/lexapro_drug?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190114005407/en/

Editor Details

Last Updated: 14-Jan-2019